Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.

Antimicrobial agents and chemotherapy·2024
Same author

Use of Multiple Pharmacodynamic Measures to Deconstruct the Nix-TB Regimen in a Short-Course Murine Model of Tuberculosis.

bioRxiv : the preprint server for biology·2023
Same author

Comparative feeding ecology of the yellow ray Urobatis jamaicensis (Urotrygonidae) from The Bahamas.

Journal of fish biology·2017
Same author

Effect of weight and frontal area of external telemetry packages on the kinematics, activity levels and swimming performance of small-bodied sharks.

Journal of fish biology·2017
Same author

The professionalisation of Irish medicine in the generations before Charles Lucas.

Irish journal of medical science·2015
Same author

Chemotaxis toward carbohydrates and peptides by mixed ruminal protozoa when fed, fasted, or incubated with polyunsaturated fatty acids.

Journal of dairy science·2014
Same journal

<i>In vitro</i> antibacterial activity of gepotidacin in combination with other antimicrobial agents against <i>Neisseria gonorrhoeae</i> isolates.

Antimicrobial agents and chemotherapy·2026
Same journal

Development of domain-specific probes of <i>Plasmodium falciparum</i> heat shock protein 70-1.

Antimicrobial agents and chemotherapy·2026
Same journal

Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies.

Antimicrobial agents and chemotherapy·2026
Same journal

Indole-based hybrids target both asexual parasites and gametocytes of <i>Plasmodium falciparum</i> and synergize with lumefantrine.

Antimicrobial agents and chemotherapy·2026
Same journal

Lineage-specific loss of the type VI secretion system in <i>Acinetobacter baumannii</i> ST19 is associated with reduced accessory genome content.

Antimicrobial agents and chemotherapy·2026
Same journal

Genomic diversity and topical antimicrobial resistance in <i>Staphylococcus aureus</i> from clinical and carriage populations in the New York-New Jersey region.

Antimicrobial agents and chemotherapy·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

A physiologically based pharmacokinetic model for capreomycin.

B Reisfeld1, C P Metzler, M A Lyons

  • 1Department of Chemical and Biological Engineering, Colorado State University, Fort Collins, Colorado, USA. brad.reisfeld@colostate.edu

Antimicrobial Agents and Chemotherapy
|December 7, 2011
PubMed
Summary
This summary is machine-generated.

This study developed the first physiologically based pharmacokinetic (PBPK) model for capreomycin, a crucial drug for multidrug-resistant tuberculosis (MDR-TB). The model aids in designing rational antibiotic regimens by predicting drug behavior in the body.

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain
06:31

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain

Published on: August 8, 2019

Related Experiment Videos

Last Updated: May 26, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain
06:31

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain

Published on: August 8, 2019

Area of Science:

  • Pharmacology
  • Microbiology
  • Computational Biology

Background:

  • Multidrug-resistant tuberculosis (MDR-TB) necessitates effective second-line antibiotic treatments.
  • Limited data and computational models exist for optimizing MDR-TB drug regimens.
  • Capreomycin is a vital cyclic peptide antibiotic used against MDR-TB.

Purpose of the Study:

  • To develop the first physiologically based pharmacokinetic (PBPK) model for capreomycin.
  • To predict the absorption, distribution, metabolism, and excretion (ADME) of capreomycin.
  • To address the knowledge gap in designing rational capreomycin administration strategies.

Main Methods:

  • Development of an exploratory physiologically based pharmacokinetic (PBPK) model.
  • Integration of targeted experimental data for model support.
  • Application of Bayesian inference and Monte Carlo methods for model calibration, validation, and testing.

Main Results:

  • Successful development of a predictive PBPK model for capreomycin.
  • Estimation of key pharmacokinetic parameter distributions, accounting for interindividual variability.
  • Support for a hypothesized mechanism of capreomycin transport into the kidney.

Conclusions:

  • The developed PBPK model is the first for an antituberculosis agent.
  • The model provides valuable insights for optimizing capreomycin therapy in MDR-TB.
  • This work advances the understanding of capreomycin pharmacokinetics and renal transport.